Table 3

Subgroup analysis of treatment-specific SNPs associated with recurrence or survival in surgery-only and surgery-plus-chemotherapy patients for the combined group (discovery plus validation sets)

Gene-SNP by outcomeLocationModelSurgery onlySurgery plus chemotherapyGroup†
HR (95% CI)*P valueHR (95% CI)*P value
VAV2: rs491220‡3‘UTRREC2.12 (1.29 to 3.50)3.06E-030.30 (0.11 to 0.83)1.99E-021
IFNGR2: rs10592933‘UTRREC0.45 (0.22 to 0.94)3.42E-022.94 (1.34 to 6.43)7.07E-032
TRA: rs20497873‘UTRREC1.93 (1.08 to 3.45)2.72E-025.79 (1.75 to 19.1)4.02E-033
PTPRC: rs2359952IntronREC1.88 (1.01 to 3.49)4.57E-024.43 (1.71 to 11.5)2.19E-033
NRAS: rs10489525IntronDOM0.59 (0.38 to 0.93)2.15E-020.42 (0.19 to 0.92)3.05E-024
TRB: rs10231513IntronDOM2.02 (1.30 to 3.14)1.66E-030.35 (0.15 to 0.81)1.36E-021
STAT4: rs3024896IntronDOM1.46 (1.01 to 2.10)4.17E-020.27 (0.08 to 0.94)3.95E-021
PTK2B: rs2322718IntronREC1.53 (1.01 to 2.33)4.62E-020.16 (0.04 to 0.71)1.57E-021
MAP3K1: rs12655019IntronDOM0.46 (0.27 to 0.79)4.96E-032.71 (1.05 to 6.99)3.94E-022
CUL1: rs243511‡IntronADD0.72 (0.56 to 0.92)7.62E-032.20 (1.10 to 4.41)2.62E-022
VAV2: rs2797826IntronDOM0.68 (0.48 to 0.99)4.64E-020.37 (0.16 to 0.82)1.53E-024
  • *HR was adjusted for gender, age, smoking status, tumor stage, performance status.

  • †Group 1 SNPs are associated with increased recurrence or death risk in surgery-only patients, but reduced risk in surgery-plus-chemotherapy patients. Group 2 SNPs are associated with reduced recurrence or death risk in surgery-only patients, but increased risk in surgery-plus-chemotherapy patients. Group three indicates SNPs associated with increased recurrence/death risk in both treatment groups, while group 4 SNPs are associated with reduced risk in both treatment groups.

  • ‡Rs521446 and rs243519 were linked with rs491220 and rs243511 (r2=1), respectively; thus the data for linked SNPs were not shown.

  • ADD, additive; DOM, dominant; REC, recessive; SNPs, single-nucleotide polymorphisms.